睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由中山大学孙逸仙纪念医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05475613,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients must have pathologically or cytologically or by radiological criteria proven hepatocellular carcinoma based on the AASLD practice guidelines

    入选标准第 2 条

  3. Child-Pugh score≤7, with no encephalopathy. Ascites that diuretics can control are permitted in this study.

    入选标准第 4 条

    The estimated survival before liver transplantation must be more than 12 weeks (Based on the Model for end-stage liver disease, MELD).

    入选标准第 8 条

  4. Eastern Cooperative Oncology Group (ECOG) Scale for Assessment of Patient Performance Status (PS score) ≤ 2; KPS score ≥60.

    入选标准第 5 条

  5. Histologically/cytologically confirmed cholangiocellular carcinoma, mixed-type liver cancer, or other rare types of liver cancer;

    排除标准第 1 条

    Recurrent liver cancer with inadequate initial treatment (i.e., no complete remission or R0 resection);

    排除标准第 2 条

  6. Female patients who are pregnant or breastfeeding;

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05475613,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Written informed consent must be obtained prior to any screening procedures. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.
  2. Patients must have pathologically or cytologically or by radiological criteria proven hepatocellular carcinoma based on the AASLD practice guidelines
  3. Patients with HCC must be beyond Milan criteria without extrahepatic metastases or lymph node metastases:
  4. Child-Pugh score≤7, with no encephalopathy. Ascites that diuretics can control are permitted in this study.
  5. Eastern Cooperative Oncology Group (ECOG) Scale for Assessment of Patient Performance Status (PS score) ≤ 2; KPS score ≥60.
  6. Have not received any immunotherapies 6 months before enrollment.
  7. Adequate bone marrow, liver, and renal function.
  8. The estimated survival before liver transplantation must be more than 12 weeks (Based on the Model for end-stage liver disease, MELD).
  9. No other lethal malignancy outside the liver in the past 5 years, such as leukemia, lung cancer, melanoma, etc.
  10. Patients with a history of hypertension should be well-controlled (< 140/90 mmHg) on a regimen of anti-hypertensive therapy.
  11. Both men and women enrolled in this trial must use adequate barrier birth control measures during the trial and 6 months after the completion of the trial.
  12. Patients voluntarily joined the study and signed informed consent with good compliance and follow-up.

排除标准:Exclusion Criteria:

  1. Histologically/cytologically confirmed cholangiocellular carcinoma, mixed-type liver cancer, or other rare types of liver cancer;
  2. Recurrent liver cancer with inadequate initial treatment (i.e., no complete remission or R0 resection);
  3. Presence of uncontrollable systemic infections, alcoholism or drug abuse, organic diseases of the heart, lungs, or brain, uncontrolled psychiatric disorders, severe mental illnesses, HIV infection, active tuberculosis, etc.;
  4. Presence of severe portal hypertension with a high bleeding risk as assessed by the investigator;
  5. History of bleeding events due to portal hypertension in the past 6 months;
  6. History of any life-threatening event in the past 6 months, including but not limited to acute myocardial infarction, unstable angina, congestive heart failure, cerebrovascular accidents, pulmonary embolism, major bleeding from other sites, etc.;
  7. Severe splenomegaly or splenomegaly-induced neutropenia (ANC < 1.5 × 10⁹/L) or thrombocytopenia (platelet count < 50 × 10⁹/L);
  8. History of grade III hepatic encephalopathy or clinical symptoms requiring long-term drainage of pleural effusion, ascites, pericardial effusion, etc.;
  9. Uncontrolled hypertension, history of hypertensive crisis or hypertensive encephalopathy;
  10. Severe pulmonary hypertension that cannot be controlled by medication;
  11. Severe coagulopathy, or those receiving thrombolytic treatment or requiring continuous anticoagulant or antiplatelet therapy for any reason;
  12. History of autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, Crohn's disease, ulcerative colitis, etc.;
  13. Major surgical procedure within 4 weeks before the first dose; History of severe allergy to any of the study drugs;
  14. Female patients who are pregnant or breastfeeding;
  15. Presence of severe psychiatric or psychological disorders.

引自 ClinicalTrials.gov, NCT05475613, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05475613,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05475613